INTRODUCTION
Recombinant DNA technology has made possible the expression of heterologous genes in a variety of animal viruses (for review, see Rigby, 1983) . The availability of a wide variety of animal virus vectors enables a foreign gene to be expressed in different cell types, at different levels and with different consequences for the host cell. Factors influencing the choice of virus vector include the types of cells or animals to be infected, whether infection leading to cell transformation or lysis is required, the number of genes to be expressed, and whether virus infectivity is to be retained. Small DNA viruses (e.g. papovaviruses) may have restricted host range and limited capacity for foreign DNA due to severe packaging constraints imposed by the icosahedral virus capsid. Consequently these virus vectors are mostly replication-defective, requiring helper virus or special cell lines for their replication. In contrast, larger viruses (poxviruses and herpesviruses) have a greater capacity for foreign DNA without destruction of infectivity and can have a wide host range.
In this review the use of vaccinia virus as an expression vector system is discussed. Perhaps the most exciting potential application of recombinant vaccinia viruses is as new vaccines against a broad range of infectious diseases. Other applications include studies of the control of vaccinia virus gene expression and studies of antibody and cell-mediated immune responses to individual antigens.
Biology of vaccinia virus
Vaccinia virus, the prototype orthopoxvirus, is a large virus with a double-stranded DNA genome and a complex virion structure. The majority of vaccinia virus particles, from 80% to greater than 99% depending on cell type and virus strain (Payne, 1979 (Payne, , 1980 , are intracellular and contain a biconcave core and structures termed lateral bodies which fit into the concavities of the core. The extracellular form of the virus which has been implicated in virus dissemination in vivo (Boulter & Appleyard, 1973; Payne, 1980) has an additional lipoprotein envelope derived from the Golgi membrane (Ichihashi et al., 1971 ; Morgan, 1976) . More than 100 polypeptides have been identified from purified virus particles (Essani & Dales, 1979) . Some of these are virus-coded enzymes such as RNA polymerase, RNA capping, methylating and polyadenylating enzymes that enable the virus to replicate in the cytoplasm of the infected cell.
The virus genome is about 187000 base pairs (bp), is 66% adenine and thymine and noninfectious when deproteinized. It possesses large inverted terminal repeats of approximately 10000 bp and the two DNA strands are linked at their termini by a single-stranded hairpin loop (Geshelin & Berns, 1974; Baroudy et al., 1982) . Considerable flexibility in the amount of DNA which can be packaged into virus particles has been observed Smith & Moss, 1983) .
Virus replication may be divided into early and late phases, defined as the periods before and 0000-7258 © 1986 SGM after DNA replication. Different sets of virus genes are expressed at these times and this temporal regulation is controlled at the transcriptional level. The vaccinia virus thymidine kinase (TK) gene is an example of an early gene (Weir & Moss, 1983 ) and a gene coding for a 28 000 mol. wt. (28K) polypeptide precursor to a structural virus protein is an example of a late gene (Weir & Moss, 1984) . A third class of virus gene that is expressed throughout the virus replicative cycle has also been identified (Mackett et al., 1984; Cochran et al., 1985b) . Interestingly, a gene of this type, which codes for a 7.5K polypeptide, initiates RNA synthesis at different sites during early and late transcription, but produces the same polypeptide upon translation (Cochran et al., 1985b) . Nucleotide sequence analyses of the DNA upstream from the virus transcriptional initiation sites have shown a very high adenine and thymine content (up to 85~o for the preceding 60 bp). These sequences do not contain eukaryotic or prokaryotic promoter consensus sequences (Venkatesan et al., 1981 (Venkatesan et al., , 1982 Weir & Moss, 1983 Berthelot et al., 1985; Rosel & Moss, 1985) . Functional analyses of these promoters using template-dependent in vitro transcription systems demonstrated that they are transcribed by vaccinia virus RNA polymerase but not eukaryotic RNA polymerase II (Puckett & Moss, 1983; Rohrmann & Moss, 1985; Foglesong, 1985; Golini & Kates, 1985) . Additionally, vaccinia virus RNA polymerase does not transcribe promoters recognized by RNA polymerase II.
For detailed reviews of poxvirus biology and replication the reader should refer to Dales & Pogo (1981) , Moss (1985) and Fenner (1985) . The important features of vaccinia virus for its utilization as an expression vector are the large genome, unique promoters and virus-coded RNA polymerase.
Strategy for insertion and expression of foreign genes
The large size of the vaccinia virus genome prevents construction of recombinant genomes by restriction endonuclease cleavage and re-ligation with foreign DNA. Even if this were practicable, production of virus from the recombinant genome would require rescue by a helper virus since virus DNA is non-infectious. A further difficulty in constructing recombinants that express foreign genes arises from the unique nature of the vaccinia virus promoters and the presence of a virus-coded RNA polymerase. This makes the utilization of these promoters essential for efficient expression of foreign genes in vaccinia virus. To overcome these problems a two-step strategy has been utilized. In the first step, a plasmid is constructed that contains the foreign gene linked to a vaccinia virus promoter. Secondly, this chimeric gene is inserted into the vaccinia virus genome by homologous recombination between virus and plasmid DNA in vivo ( Fig. 1) Mackett et al., 1985b) .
The construction of the chimeric gene should be carefully engineered to ensure that the authentic foreign protein is produced by the recombinant virus. This requires knowledge of the nucleotide sequence of both the foreign gene and the vaccinia virus promoter and also of the transcriptional initiation site of the vaccinia virus gene. Ideally the vaccinia virus promoter should be isolated to retain the RNA start site but removing the translational start site. The foreign protein-coding sequence is then positioned as close as possible to the vaccinia RNA start site ensuring that the first downstream ATG triplet is the initiation codon of the foreign gene.
Insertion of the chimeric gene into the virus genome is accomplished by flanking the gene with vaccinia virus DNA taken from a non-essential region of the virus genome. The resultant plasmid is then transfected into cells infected with vaccinia virus. Within these cells the homologous DNA sequences of the plasmid and the virus genome enable recombination to occur and result in transfer of the chimeric gene from the plasmid to the virus genome. Recombinant genomes are then replicated and packaged into infectious virus (Fig. 1) . The site at which the foreign gene is inserted is determined by the flanking vaccinia virus DNA of the plasmid. Obviously the construction of infectious recombinant viruses requires this DNA to be from a region of the virus genome non-essential for virus growth and several such regions have been identified. These include a region towards the left-hand end of the virus genome that is deleted in some mutants Panicali et al., 1981) , an internal position within the HindIII F fragment of the W R strain of virus (Panicali & Paoletti, 1982) Mackett et al., 1982) . Although any non-essential site can be utilized, the TK gene has been extensively used since insertion of foreign DNA within the TK coding sequences destroys TK enzyme activity. Consequently, recombinant viruses are TK-and may be distinguished from the TK + wild-type (wt) virus by plaquing on a TK-cell line in the presence of 5-bromodeoxyuridine (BUdR) (Mackett et al., 1982; Smith et al., 1983a) . Other methods for selecting recombinant viruses are described below.
Insertion and expression of foreign genes has also been achieved without directly engineering promoters (Panicali & Paoletti, 1982; Panicali et al., 1983; Paoletti et al., 1984; Perkus et al., 1985) . In these cases the foreign gene alone is inserted into a non-essential site of the virus by homologous recombination using a plasmid vector. Expression of the foreign gene depends upon a vaccinia virus promoter being adjacent to the site of insertion within the vaccinia virus genome. The procedure is technically simpler but can utilize promoters only from non-essential genes, makes optimization of expression difficult and can lead to the formation of fusion proteins with unpredictable properties. Despite these complications this procedure has been (Mackett et al., 1984) . A generalized co-insertion vector is illustrated in (c) and pSC11 (d) is a specific example (Chakrabarti et al., 1985) . Flanking vaccinia DNA is indicated as thick lines, plasmid DNA as a thin line and vaccinia promoters (P) as open boxes. The direction of transcription from these promoters is indicated by external arrows. PT.s is a vaccinia virus promoter expressed throughout the replicative cycle (Mackett et al., 1984) and P~ 1 is a late vaccinia virus promoter (Wittek et aL, 1984a) . The direction of transcription and position of the vaccinia virus TK coding sequences in pGS20 and pSC11 is indicated by the internal arrows. Amp r, plasmid ampicillin resistance gene; fl-gal,//-galactosidase.
successfully used to express various foreign genes and to rapidly identify regions of the genome non-essential for replication of the virus in cell culture Perkus et al., 1985) .
Design of plasmid vectors
To simplify the rapid construction of recombinant viruses expressing foreign genes a series of plasmid vectors, called insertion vectors, have been developed (Mackett et al., 1982 (Mackett et al., , 1984 Smith et al., 1983 a; Kieny et al., 1984; Franke et al., 1985; Boyle et al., 1985) . The design of these plasmids has been based upon nucleotide sequence data of early and late vaccinia virus promoters (Venkatesan et al., 1981; Weir & Moss, 1983 Berthelot et al., 1985) . The structure of generalized plasmid insertion vectors and specific examples are given in Fig. 2 . Similar vectors using other vaccinia virus promoters have been described (Mackett et al., 1984; Weir & Moss, 1984; Boyle et al., 1985) , and further modifications made by addition of synthetic linkers or oligonucleotides (Mackett et aL, 1985 a) .
The essential features of these plasmids are a vaccinia virus promoter with multiple unique restriction endonuclease sites just downstream of the RNA start site, translocated within the body of the virus TK gene. DNA fragments coding for any contiguous protein-coding sequences can then be easily inserted adjacent to the vaccinia virus promoter. With correct engineering, authentic foreign proteins are produced and problems associated with incorrect codon phasing and unpredictable properties of fusion proteins avoided. This strategy will enable other vaccinia virus promoters to be utilized as they become identified and characterized.
More recently, additional types of plasmid insertion vectors have been constructed that include two vaccinia virus promoters. One of these is used to drive expression of a marker gene that facilitates isolation of recombinant virus, while the second is used to express the desired foreign gene. In this way a recombinant virus that expressed both/~-galactosidase and hepatitis B virus surface antigen (HBsAg) was constructed (Chakrabarti et al., 1985) . The use of these vectors for selection of recombinant virus is discussed more fully below.
Generation and selection of recombinant viruses
Once the foreign protein-coding sequence has been cloned into a plasmid insertion vector under control of a vaccinia virus promoter, the foreign gene is inserted into the virus by homologous recombination in vivo. Cells infected with wt vaccinia virus at low multiplicity of infection (0.05 p.f.u./cell) are transfected with calcium phosphate-precipitated DNA in a manner identical to that used for marker rescue (Sam & Dumbell, 1981; Weir et al., 1982; Nakano et al., 1982; Condit et al., 1983; Ensinger & Rovinsky, 1983; Drillien & Spehner, 1983) . The efficiency of marker rescue is not increased by either glycerol or dimethyl sulphoxide shocks but is increased by co-precipitation of plasmid DNA with wt vaccinia virus DNA (Sam & Dumbell, 1981; Nakano et al., 1982; Ensinger, 1982) . Similarly the frequency at which recombinant viruses are generated is also increased in this way.
Other investigators have used an alternative transfection procedure de la Salle et al., 1985) . They argue that the formation of recombinant viruses is limited to those few cells which are competent for DNA transfection. Therefore, to reduce the background of nonrecombinant parental viruses that replicate in non-transfected cells, cells are infected with a temperature-sensitive (ts) mutant of vaccinia virus at the non-permissive temperature and then transfected with a mixture of wt vaccinia DNA and the desired plasmid vector. Virus multiplication can occur only in cells in which the ts lesion is complemented by the transfected wt vaccinia DNA. Since these cells will presumably also take up the plasmid DNA, recombinant genomes may be formed. This procedure reduces background non-recombinant virus but is limited to those strains of virus for which ts mutants with low reversion frequencies are available. It is also possible that the ts mutants contain other mutations which, although not conditionally lethal, may affect other virus properties such as growth rate or pathogenicity.
Using standard procedures with wt virus, at best only 0.1~ of total progeny virus from a transfection experiment are recombinants. Consequently screening or selection methods that distinguish between recombinant and wt virus are used. As mentioned above, insertion of a foreign gene within the coding sequence of the vaccinia virus TK allows selection of the recombinants on the basis of their TK-phenotype. Using this strategy the majority of the TKplaques are recombinant viruses while the others are spontaneous TK mutants selected by plaque formation in BUdR. These TK-viruses can be distinguished by a simple DNA :DNA hybridization protocol (Mackett et al., 1982) or by screening for expression of the foreign gene using immunological techniques (Mackett et al., 1985b; Mackett & Arrand, 1985) . An alternative selection strategy is to express a gene that is itself a selectable marker. For example, expression of herpes simplex virus (HSV) TK in vaccinia virus TK-mutants (Mackett et al., 1982; Panicali & Paoletti, 1982) enables TK + vaccinia virus recombinants to be selected in TKhost cells using HAT medium. The neomycin resistance gene, potentially a more generally applicable dominant selectable marker, has also been expressed in vaccinia virus . Recombinant virus expressing this gene was able to plaque in the presence of the synthetic antibiotic G418 whereas wt virus was unable to produce plaques. The advantage of using this selectable marker is that recombinants can be generated in all the cell lines that support the growth of vaccinia virus and that any non-essential region of the virus genome can be used for insertion of the gene.
Another attractive way of screening for recombinants is based upon the expression of/~-galactosidase in vaccinia virus. Incorporation of 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal) in the agarose overlay allows visual detection of recombinants expressing /~-galactosidase as blue plaques (D. Panicali, personal communication; Chakrabarti et at., 1985; Newton et al., 1986) . Plasmids that contain the/~-galactosidase gene driven by one vaccinia M. MACKETT AND G. L. SMITH virus promoter and another foreign gene linked to a second virus promoter can be used to generate recombinant viruses which simultaneously acquire and express both foreign genes and which can be visually selected by virtue of the fl-galactosidase expression (Fig. 2) (Chakrabarti et al., 1985) . These authors also describe a procedure for selection of recombinant viruses based upon the removal of the fl-galactosidase gene from a parental virus expressing this gene. In this method a foreign gene (e.g. HBsAg), is inserted into the virus with simultaneous deletion of flgalactosidase. The virus recombinant expressing HBsAg is then selected as a white plaque among parental blue plaques. This procedure has the advantage that fl-galactosidase is not expressed by the final recombinant virus while the ability to produce the virus on any susceptible cell line is retained. Beta-galactosidase expression by the recombinant virus may be undesirable in some cases; for example, immunization of animals that possess immunity to fl-galactosidase acquired through natural bacterial infection may result in a diminished immune response against other foreign antigens expressed by the recombinant virus.
Expression of selectable genes such as fl-galactosidase, HSV TK and neomycin resistance may also be used to generate defined deletions within the vaccinia virus genome. If recombinants are formed with the desired deletion, the approach will have identified genes non-essential for virus growth in tissue culture and may help elucidate the function of these deleted genes.
In conjunction with selective protocols (above) other methods of screening for recombinant viruses have also been described. Recombinant viruses can be distinguished from parental virus by an in situ plaque DNA :DNA hybridization protocol (Villareal & Berg, 1977; Panicali & Paoletti, 1982; Smith & Moss, 1983) . Cell monolayers containing plaques are transferred to a nitrocellulose sheet and the filter is treated to denature, neutralize and fix the DNA. Hybridization of 32p-labelled foreign gene DNA to the filter is used to detect the recombinant viruses in the original monolayer. These viruses can be recovered from the corresponding position of the agarose overlay used in the plaque assay or, alternatively, from a second nitrocellulose filter that had been pressed against the primary filter.
Recombinant viruses expressing foreign antigens may also be identified by immunological recognition of the foreign protein. Binding of antibody to the foreign gene product in infected cells may be detected using 125I-labelled Protein A from Staphylococcus aureus and autoradiography (Panicali et al., 1983 ; Smith et al., 1983 b) or by use of an enzyme-linked second antibody directed against the primary antibody. Individual recombinant plaques can then be detected using the appropriate chromogenic substrate for the antibody-linked enzyme (Mackett & Arrand, 1985; Newton et al., 1986) .
Whatever the choice of selection method for isolation of recombinant virus, the virus is always routinely plaque-purified at least twice before larger stocks are grown. Virus is isolated from cytoplasmic extracts of infected cells by Dounce homogenization and sucrose density gradient centrifugation because the majority of infectious progeny virus remains cell-associated (Joklik, 1962) . Recombinant viruses derived from the WR strain usually give virus stocks with titres in excess of 10 l° p.f.u./ml after recovery from sucrose gradients. It is noteworthy that this virus has a different composition (see above) from the extracellular released virus.
Characterization of recombinant viruses
To confirm the nature of recombinant virus, the genomic DNA is analysed by restriction endonuclease digestion, Southern blotting and hybridization with specific 32p-labelled DNA probes. In every recombinant analysed and reported in the literature the foreign gene has integrated at the predicted genomic locus, there are no compensatory deletions or other genomic rearrangements and the recombinants are stable upon serial passage. The ability to retain all wt virus DNA contrasts with other vector systems, such as simian virus 40 (SV40) and retroviruses which require deletion of virus sequences in order to accommodate foreign genes. This enables vaccinia virus recombinants to retain infectivity since no essential virus functions are affected. Moreover, the capacity of these recombinants for foreign DNA is very large. Twenty-five kilobase pairs of DNA were inserted into vaceinia virus without compensatory deletions and did not affect the growth rate or infectivity of the recombinant virus (Smith & Moss, 1983) . This flexibility of genome size indicates that the physical constraints on packaging vaccinia virus DNA are much less stringent than for viruses that possess icosahedral symmetry. Viable deletion mutants of rabbitpox and vaccinia viruses (Moyer & Rothe, 1980; Moss et al., 1981) have deletions of up to 10 kb; thus, at least 35 kb of foreign DNA may be introduced into vaccinia virus. This will allow the simultaneous insertion and expression of many genes in poxvirus vectors and has important implications for the construction of polyvalent vaccines (see below).
Expression o f foreign genes
The probability that the expression of foreign genes would depend upon use of vaccinia virus promoters was confirmed in early experiments with HSV TK and HBsAg (Panicali & Paoletti, 1982; Mackett et al., 1982; Smith et al., 1983a) . Insertion of a 265 bp DNA fragment, which included the 235 bp upstream and 30 bp downstream of a vaccinia virus transcriptional initiation site, in front of the HSV TK gene was sufficient to drive expression of this gene (Mackett et al., 1982) . If the promoter was inserted in the opposite orientation, or not at all, no expression was detected. Similar conclusions were reached with the HBsAg gene and influenza virus haemagglutinin (HA) genes (Smith et aL, 1983a, b) . However, low levels of expression in the absence of correctly engineered promoters have been observed late in infection (Smith et al., 1983 a; Mackett et al., 1984) . This is probably attributable to the length and heterogeneity of late virus mRNAs which might function inefficiently as polycistronic messages. Nonetheless, utilization of vaccinia virus promoters is essential for high levels of expression and additional promoters are being characterized to this end.
The functional characterization of vaccinia virus promoters has been simplified by the development of a transient expression system (Cochran et al., 1985 a) . In this system plasmids containing vaccinia virus promoters that are linked to easily assayable enzymes such as chloramphenicol acetyltransferase (CAT) are transfected into cells infected with vaccinia virus at high multiplicity. The CAT activity may then be rapidly measured within infected cell lysates without the laborious isolation and growth of recombinant viruses. These studies coupled with in vitro mutagenesis of vaccinia virus promoters have demonstrated that DNA fragments as small as 31 bp can function efficiently as promoters in vaccinia virus-infected cells (Cochran et al., 1985b) . The level of expression obtained is dependent upon the vaccinia virus promoter used and its positioning with respect to the foreign protein-coding sequence. Interestingly, the presence of an SV40 transcriptional enhancer element upstream of a vaccinia virus promoter did not increase foreign gene expression. A feature that is complicating the use of some vaccinia virus promoters, particularly late promoters, is the close proximity of the 5' end of the transcribed RNA to the first downstream AUG which initiates the open reading frame (Weir & Moss, 1983 Berthelot et al., 1985) . Consequently, without in vitro mutagenesis it is difficult to construct chimeric genes in which the first downstream ATG is provided by the foreign gene. However, these promoters may be useful for the expression of fragments of foreign proteins which require a translation initiation codon to be provided. Whether the close proximity of the transcriptional and translational initiation sites is important for optimal expression of genes in vaccinia virus remains to be seen, but it is apparent that translation of many vaccinia virus mRNAs occurs without the consensus sequence that surrounds the translation start site of many eukaryotic mRNAs (Kozak, 1983) .
All vaccinia virus genes and mRNAs analysed so far indicate the absence of introns and mRNA splicing. This is not altogether surprising for a virus which replicates in the cytoplasm of infected cells but it has implications for the expression of foreign genes that contain introns. In these cases cDNA copies of mature mRNAs are required. Paradoxically, the inability to splice mRNAs may be advantageous in some cases since cDNA copies of genes from RNA viruses may contain cryptic splice sites. Although these sites may not be recognized in the cells infected by the RNA virus, if introduced into the cell nucleus by other expression vectors mRNA splicing may occur and expression can be prevented. (1985) G. L. Smith, unpublished data also enabled isolation of the recombinant virus (Mackett et al., 1982; Chakrabarti et al., 1985; Franke et al., 1985) . Table 1 lists five enzymes that have been expressed in vaccinia virus, all of which have been detected enzymically. Chloramphenicol acetyltransferase and the product of the neomycin resistance gene are bacterial enzymes absent in eukaryotic cells. CAT and flgalactosidase expression may be sensitively assayed and the former has been extensively used to study the temporal control and level of expression obtained from vaccinia virus promoters (Mackett et al., 1984; Weir & Moss, 1984; Cochran et al., 1985a, b) . Expression of flgalactosidase and influenza virus neuraminidase has also been detected immunologically (Chakrabarti et al., 1985; Newton et al., 1986; G. L. Smith, unpublished data) .
Detection of foreign gene expression
In the majority of cases the expression of foreign antigens has been detected immunologically by immunoprecipitation, Western blotting, radioimmunoassay, immunofluorescence or enzyme-linked immunoassays. Analyses of the foreign gene products on SDS-polyacrylamide gels has demonstrated that with correct DNA engineering, the proteins are of the predicted size and undergo appropriate post-translational modifications. Glycosylation (Smith et aL, 1983 a, b; Kieny et al., 1984; Wiktor et al., 1984; Cremer et al., 1985; Mackett et al., 1985a; Mackett & Arrand, 1985; Rice et al., 1985; de la Salle et aL, 1985 ; Chakrabarti et al., 1986; Hu et al., 1986) , proteolytic cleavage Chakrabarti et al., 1986; Elango et al., 1986; Ball et al., 1986 ) and carboxylation (de la Salle et al., 1985) of foreign gene products have been reported. The foreign gene product is also transported normally and has been detected on the cell surface (Smith et al., 1983 b; Cremer et al., 1985; Mackett et al., 1985 a; Wiktor et al., 1984; Stephens et al., 1986; Chakrabarti et al., 1986; Elango et al., 1986; Ball et al., 1986) or found to be excreted from infected ceils (Smith et al., 1983a; Paoletti et al., 1984; Langford et al., 1986) . A few cases of incorrect post-translational modification and transport have been reported. The sporozoite surface antigen of the human and simian malarial parasites Plasmodium knowlesi and P. falciparum appears to have a higher molecular weight than expected on SDS-polyacrylamide gels. The fusion protein of respiratory syncytial virus (Wertz et al., 1985) and the human T cell leukaemia virus type III (HTLV-III) envelope protein (Chakrabarti et aL, 1986) produced by vaccinia virus recombinants are not proteolytically cleaved. In these cases the incomplete proteolytic processing is probably due to differences in proteases present in the cells that normally produce these proteins and the cells infected by the vaccinia virus recombinants. When the vaccinia virus-HTLV-III envelope recombinant was grown in a lymphoid cell line that supports the growth of HTLV-III, correct processing of the envelope protein occurred (Chakrabarti et al., 1986) . Table 2 lists the virus glycoproteins expressed by recombinant vaccinia viruses and also indicates whether vaccination of experimental animals has resulted in neutralizing antibodies or protection against the appropriate virus. (1985) by a number of factors including the strain and dose of recombinant virus, the route of administration, the level of expression of foreign protein and the degree of existing immunity to vaccinia virus. In animals with no existing immunity to vaccinia virus, dermal inoculation of the recombinant virus has resulted in a typical primary vaccinial lesion which healed in 2 to 3 weeks. During this period no viraemia was detected (Smith et al., 1983a) and the animals were otherwise healthy. Strong, systemic antibody responses against the foreign protein have often resulted from this primary vaccination (Table 2) . Significantly, re-vaccination of experimental animals with the same recombinant virus can result in boosting of antibody levels despite the existing immunity to vaccinia virus (Mackett et al., 1985a; Perkus et al., 1985; Smith et al., 1985) . Animals that were immunized first with wt vaccinia virus and subsequently with a recombinant vaccinia virus expressing a foreign antigen were still able to mount an immune response against the foreign antigen Smith et al., 1985) . However, levels of immunity were lower than those induced by a primary vaccination.
Animals inoculated nasally with an aerosol containing a vaccinia virus recombinant expressing the influenza virus HA have produced local secretory IgA antibody against the HA . These antibodies were not detected when the virus was administered by dermal scarification and their presence correlated with protection against upper respiratory infection by influenza virus. This study illustrated the importance of different routes of virus administration in the type of immune response produced.
In many cases the antibody responses against the foreign proteins have neutralized virus infectivity in vitro. More importantly, experimental animals have been protected against subsequent challenge with the appropriate pathogen (Smith et al., 1983b; Paoletti et al., 1984; Moss et al., 1984; Kieny et al., 1984; Wiktor et al., 1984; Mackett et al., 1985a; Cremer et al., 1985; Elango et al., 1986) .
Cell-mediated immune responses have also been reported against the foreign gene product (Bennink et al., 1984 (Bennink et al., , 1986 Wiktor et al., 1984; Yewdell et al., 1985; McMichael et al., 1986) . Cytotoxic T lymphocytes that recognize the HA or nucleoprotein of influenza virus or the rabies virus glycoprotein were induced by recombinant vaccinia viruses expressing these genes. The ability of the live recombinant virus to stimulate both humoral and cell-mediated immune responses against the foreign gene product enhances the potential of these viruses as new live vaccines (see below).
Applications of recombinant vaccinia viruses

Study of vaccinia virus gene regulation
During infection of cells by vaccinia virus the virus genes are expressed in a temporally controlled manner. This control is mediated at the transcriptional level but the mechanism(s) remains unknown. Although nucleotide sequence analyses have demonstrated that the regions upstream of vaccinia transcriptional start sites appear different from those of other eukaryotic promoters, a correlation of nucleotide sequence and function is needed. The expression of easily assayable enzymes (e.g. CAT) under the control of these promoters in vaccinia virus is providing this correlation (Mackett et al., 1984; Cochran et al., 1985a, b; Weir & Moss, 1984) . Using this approach and in vitro mutagenesis of promoters, it has been demonstrated that DNA fragments of only 31 bp upstream from the transcriptional initiation site are sufficient to drive expression. Moreover, the level of expression from these small DNA fragments was very similar to that obtained from much larger DNA fragments (Cochran et al., 1985 b) . It was also noted that after translocation of promoters from various places within the virus genome to the TK gene locus, the promoter still exhibited the same temporal regulation (Mackett et al., 1984; Weir & Moss, 1984) . Therefore, the factors controlling both the time and level of expression reside in the same short DNA sequences. Before conclusions can be drawn about conserved sequences responsible for controlled expression of early versus late genes, more promoters need to be analysed in detail. Nonetheless, sequence analyses have shown that regions upstream from vaccinia virus late genes are significantly less rich in adenine and thymine residues than the corresponding regions of early genes which can be up to 90~ adenine and thymine (Weir & Moss, 1983 Rosel & Moss, 1985) .
Additional vaccinia virus promoters are being identified by mapping and sequencing of virus genes and also by shotgun cloning of small virus DNA fragments upstream of selectable genes (Vassef et al., 1985) . In the latter case, if the DNA cloned upstream of the selectable gene is able to drive its expression, recombinants can be isolated by virtue of expression of the foreign gene.
Immunological tools
Vaccinia virus expression vectors have several immunological applications. The most straightforward application is to raise monospecific antiserum against a known protein or the product of an open reading frame of unknown function. The antiserum may then be used to examine the synthesis and location of the protein within its usual environment. Vaccinia virus recombinants are particularly good for raising antisera against glycoproteins since these are expressed on the infected cell surface where they are easily recognized by the host animal's immune system. However, good immune responses have also been detected against internal proteins such as the nucleocapsid proteins of vesicular stomatitis virus (VSV) and influenza virus (Mackett et al., 1985 a; Jones et al., 1986; Yewdell et al., 1985) . For virus genes, the antisera may be tested for the ability to neutralize virus infectivity or prevent plaque formation. Antisera raised against virus open reading frame products of unknown function can be used to identify potential targets of neutralizing immune responses.
Foreign genes expressed in recombinant virus-infected cells can also be used to test whether immune sera contain antibodies against the foreign protein. This could form the basis of diagnostic tests for previous exposure to the pathogen from which the gene was derived. Recombinant virus-infected cells expressing a foreign protein may also be used as target antigen against which monoclonal antibodies or T cell clones of unknown specificity may be screened.
Perhaps a more unique application of recombinant viruses is the analysis of cell-mediated immune responses to individual antigens. Two observations make such experiments possible. First, cells infected with recombinant vaccinia viruses can express the foreign antigen on the cell surface in conjunction with antigens of the major histocompatibility complex. These cells may be recognized and lysed by autologous cytotoxic T lymphocytes (CTLs) directed against the foreign antigen. Since vaccinia virus can infect a very broad range of cells a large variety of infected target cells may be tested in cytotoxicity assays McMichael et al., 1986) . The second observation is that recombinant vaccinia viruses can themselves prime and stimulate cell-mediated immune responses in vaccinated animals (Bennink et al., 1984; Wiktor et al., 1984; Yewdell et al., 1985) . The specificity of the CTLs induced by these vaccinations can be tested on target cells infected with different strains and types of the appropriate virus. Using this approach and recombinant vaccinia viruses expressing influenza virus genes, it has been shown that the influenza HA induces CTLs which are mostly non-cross-reactive among different influenza A viruses (Bennink et al., 1984 (Bennink et al., , 1986 . Conversely, the influenza virus nucleoprotein is a major target antigen for anti-influenza A virus cross-reactive CTLs . Similar conclusions have been reached from studies using transfection procedures to introduce influenza virus genes into target cells (Townsend et al., 1984) .
Live recombinant vaccines
Recombinant vaccinia viruses have considerable potential as live vaccines against a wide range of pathogens. This has been recognized by the WHO which convened meetings on this subject in Washington late in 1984 and in Geneva in 1985. Much of the interest stems from the successful use of vaccinia virus for the immunoprophylaxis and eventual global eradication of smallpox (WHO, 1980) . Many of the features of vaccinia virus which made it such an effective vaccine against smallpox are likely to be retained by recombinant vaccinia viruses. The cheapness of the vaccine to manufacture and administer, its stability without refrigeration, potency as a single inoculation, and stimulation of both antibody and cell-mediated immune responses are all advantages traditionally associated with vaccinia virus. A disadvantage was the rare occurrence of serious complications following vaccination (Lane et al., 1969) . The successful eradication of smallpox also reflected the acute easily recognizable nature of the disease and the lack of an animal reservoir for the virus. Many of the diseases against which recombinant vaccinia viruses may now be turned are chronic infections with large human or animal reservoirs and therefore their control or eradication pose greater problems than that of smallpox. Despite this, the attractions of vaccinia virus as an immunizing vehicle in human and veterinary medicine are numerous and preliminary results with experimental infections in animals have proved very encouraging.
So far experimental animals have been protectively immunized against influenza virus (Smith et al., 1983b; Small et al., 1985) , hepatitis B virus , HSV (Paoletti et al., 1984; Cremer et al., 1985) , rabies virus Kieny et al., 1984) , VSV (Mackett et al., 1985 a) and respiratory syncytial virus (Elango et al., 1986) . Recombinants expressing antigens from other pathogens have also been shown to induce antibodies that react with the pathogen in vitro (Tables 2 and 3) .
Since a considerable proportion of the world's human population possess some degree of immunity to vaccinia virus owing to previous smallpox vaccination, concern has been voiced about the effectiveness of re-vaccination with recombinant vaccinia viruses. This may not be such a problem as previously thought for the following reasons. First, since smallpox vaccination has now been discontinued, with the exception of some military personnel, there is an ever increasing non-immune population, including the great majority of children under 10 years old. Second, during smallpox vaccination programmes re-vaccination frequently occurred with good evidence of the virus replicating on secondary vaccination. There is also evidence that re-vaccination of experimental animals results in boosting of antibody responses to foreign genes (Mackett et al., 1985 a; Perkus et al., 1985) . Recently accidental immunization of a human with a recombinant vaccinia virus occurred. Despite a previous smallpox vaccination, the individual developed a local vaccinial lesion and antibodies against the foreign gene expressed by the recombinant virus (Jones et al., 1986) .
The other major concern about the potential utilization of recombinant vaccinia viruses as vaccines is safety. Complications of smallpox vaccination are widely documented (Lane et al., 1969 ; for review, see Arita & Fenner, 1985) . In the study of Lane et al. (1969) , 14.2 million vaccinations in the U.S.A. in 1968 resulted in 572 complications and nine deaths. Complications were tenfold higher in primary vaccinees and most common in children under 1 (Conybeare, 1964; Dick, 1966) . In addition to these complications associated with wild-type vaccinia virus the virulence and pathogenicity of recombinant viruses may be altered by inactivation of vaccinia genes or expression of a foreign gene. Conceivably, the expression of a foreign cell surface glycoprotein could alter the tissue tropism or membrane fusion properties of the recombinant virus. Therefore each recombinant virus needs to be carefully evaluated.
Stable attenuated strains of virus that retain adequate immunogenicity are needed. During the smallpox vaccination campaigns several attenuated strains of vaccinia were produced (van der Noordaa, 1964; Kempe et al., 1968; Tagaya et al., 1973) and the LC16m8 strain has been licensed for use in Japan since 1975 (see Hashizume et al., 1985) . These strains were derived by long term passage in tissue culture and selected in a variety of empirical ways so the virus genes that were the targets for attenuation were not defined. However, now that specific deletions or insertions in the vaccinia genome may be made, it is possible to construct attenuated viruses with defined mutations. As more vaccinia virus genes are identified and their functions determined, rational design of attenuated viruses will be possible. Already, two virus genes have been identified which affect pathogenicity. Inactivation of the TK gene results in a marked reduction in virus pathogenicity (Bullet et al., 1985; J. D. Williamson, personal communication) and it is likely that deletion of the virus 19K polypeptide that has homology to epidermal growth factor will also reduce pathogenicity.
Another goal is to increase the level of expression of foreign genes. This requires isolation and functional characterization of more vaccinia virus promoters and an understanding of the factors that affect efficient translation of mRNAs in vaccinia virus-infected cells. With the isolation and utilization of promoters from genes coding for the major structural virus components (Weir & Moss, 1984; Wittek et al., 1984a, b; Rose1 & Moss, 1985) higher levels of expression are anticipated, which should stimulate stronger immune responses in vaccinated animals.
The level and type of immune response is also influenced by the route of vaccination and by the way the foreign antigen is presented to the immune system. Langford et al. (1986) showed that the immune response to a malarial antigen that was excreted from infected ceils was poor, but the immunogenicity of the antigen was dramatically increased when it was anchored on the surface membrane of the virus-infected cell. Small et al. (1985) demonstrated that nasal secretory IgA against influenza virus HA was produced only in animals that received a nasal immunization and that this correlated with prevention of local infection by influenza virus.
The large capacity of vaccinia virus for foreign DNA (Smith & Moss, 1983 ) also permits simultaneous expression of multiple foreign antigens, creating polyvalent vaccines . Potential vaccines of this type could be designed to fit the needs of different geographical areas; for example, a vaccine that simultaneously immunized against hepatitis B and Epstein-Barr viruses in southern China would be highly desirable. A major advantage of a polyvalent vaccine is that while simultaneous immunization against multiple pathogens is obtained, the risks of vaccination are experienced only once. The potential advantages of immunization against diseases causing high morbidity and mortality such as the acquired immunodeficiency syndrome, hepatitis B or malaria would seem greatly to outweigh the rare adverse complications. Nonetheless, the development of new safer virus strains is necessary and will increase the attractiveness of this type of vaccine.
